Lexeo Therapeutics (LXEO) director awarded options on 35,000 shares at $4.70

Rhea-AI Filing Summary

Lexeo Therapeutics director Steven Altschuler received a grant of options covering 35,000 shares of Common Stock. The stock options have an exercise price of $4.70 per share and expire on June 24, 2036. All 35,000 underlying shares vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, as long as he remains in continuous service. Following this award, he holds 35,000 stock options directly, and the transaction reflects a compensation-related grant rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Altschuler Steven

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	35,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 35,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 35,000 shares Exercise price: $4.70 per share Expiration date: June 24, 2036 +1 more

4 metrics

Option grant size 35,000 shares Stock Option (right to buy) awarded to director

Exercise price $4.70 per share Conversion or exercise price of granted options

Expiration date June 24, 2036 Option term end date

Post-transaction derivative holdings 35,000 options Total shares following transaction for this option grant

Key Terms

Stock Option (right to buy), grant/award acquisition, Common Stock, exercise price, +2 more

6 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"conversion_or_exercise_price: 4.7000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-24T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

continuous service financial

"subject to the Reporting Person's continuous service on such date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:46 PM Accepted by SEC EDGAR 06/29/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altschuler Steven

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.7	06/25/2026		A		35,000		(1)	06/24/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.

	/s/ Youjin Choi, Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Lexeo Therapeutics (LXEO) director Steven Altschuler report on this Form 4?

Steven Altschuler reported receiving a stock option grant for 35,000 shares of Lexeo Therapeutics Common Stock. The options were awarded as compensation, not bought on the open market, and give him the right to purchase shares at a fixed exercise price in the future.

How many Lexeo Therapeutics (LXEO) shares are covered by Steven Altschuler’s new option grant?

The new stock option award covers 35,000 shares of Lexeo Therapeutics Common Stock. These options give him the right to buy that number of shares once vested, subject to the vesting schedule and continuous service requirements described in the Form 4 footnote.

What is the exercise price and expiration date of Steven Altschuler’s Lexeo Therapeutics options?

The stock options have an exercise price of $4.70 per share and an expiration date of June 24, 2036. This means he can choose to buy shares at $4.70 any time after vesting and before the June 2036 expiration, if he elects to exercise.

When do Steven Altschuler’s Lexeo Therapeutics stock options vest?

All 35,000 option shares vest on the earlier of one year after the grant date or the next annual meeting of stockholders. Vesting is conditioned on his continuous service with Lexeo Therapeutics through that date, according to the Form 4 footnote disclosure.

Is Steven Altschuler buying or selling Lexeo Therapeutics (LXEO) stock in this Form 4?

He is not buying or selling shares on the market in this filing. The Form 4 reports a compensation-related grant of stock options, giving him the right to purchase shares later, rather than an immediate open-market transaction in Lexeo Therapeutics stock.

How many Lexeo Therapeutics derivative securities does Steven Altschuler hold after this transaction?

After the reported grant, he holds 35,000 stock options directly, as shown by the total shares following the transaction. These represent rights to acquire Common Stock in the future, subject to vesting and the June 24, 2036 expiration date specified in the Form 4.